Novo Nordisk and Eli Lilly Expand Obesity Drugs Globally

Novo Nordisk and Eli Lilly (ticker: LLY) are expanding beyond their core markets to boost the reach of obesity drugs, as global usage among eligible patients remains at just 1%-2%.

Details

According to a report from GuruFocus, obesity drugs face significant pricing and access barriers, prompting both companies to seek opportunities in new markets. Eli Lilly, which produces Zepbound, and Novo Nordisk, the maker of Wegovy, are working to broaden distribution outside the US and Europe.

Context

Only 1%-2% of eligible patients worldwide use obesity drugs, despite their high efficacy. The main reasons are high costs and lack of insurance coverage in many countries. Additionally, healthcare infrastructure in some emerging markets is not yet ready to accommodate these treatments.

What This Means for Investors

International expansion represents a significant growth opportunity for Eli Lilly and Novo Nordisk, especially if they can reduce costs or improve access through local partnerships. However, the biggest challenge remains overcoming regulatory and pricing hurdles in new markets.